News Focus
News Focus
icon url

Couch

05/08/17 3:58 PM

#254383 RE: Subjugator #254382

It does look like a solid product but how long will their Phase 3 trial take?
icon url

hondobud

05/08/17 4:28 PM

#254389 RE: Subjugator #254382

Looks like the PH2 testing of the CR845 was an intravenous drug study used in conjunction with morphine to reduce pain in post operative situations, definitely a long stretch to assume this will be rendering all opioids obsolete.
icon url

jtf3

05/08/17 6:46 PM

#254406 RE: Subjugator #254382

I agree 100%
icon url

lasers

05/08/17 7:21 PM

#254410 RE: Subjugator #254382

SequestOx-II is an Oxycodone opioid drug with activates the U-receptor, Mu, the action of which is well known on the human body for many hundreds of years

CR845 activates the K-opioid receptor which is unlike the U-opioid as for Morphine, Codeine, Oxycodone etc.

Little is known for the Kappa receptor drugs safety especially on the unborn fetus.

CARA's Phase2 trial

"A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee"

Complete birth control must be exercised throughout the trial by both Female and Male participants.

If female:
Of childbearing potential - the patient must be willing to practice an acceptable form of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence from sexual intercourse) for the duration of treatment and for at least 3 days following the last dose of study drug.
Of non-childbearing potential - the patient must be surgically or biologically sterile (hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or postmenopausal for at least 1 year).
If male, the patient must be surgically or biologically sterile. If not sterile, the patient must agree to use an acceptable form of birth control with a heterosexual partner (as described in inclusion criterion #9) or abstain from sexual relations during the treatment period and for 3 days following the last dose of study drug.



Safety of Orally Administered CR845 is unknown and will require IMO at least a Phase3 of perhaps several thousand persons to be assured of its safety which will require several years.
icon url

Jimmy Joe

05/08/17 9:12 PM

#254419 RE: Subjugator #254382

CR845 approved it will effectively render all opioids, including abuse deterrent ones absolete



Highly doubt that. Opiods have been here for centuries. Doubt highly they will be replaced anytime soon.

Good luck with CARA. 5 years away if at all?
A company that generates zero revenues more than likely.
Yeah.... good luck on that one.

Meanwhile I'll stick to Elite. Thanks anyway! LOL